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RESEARCH ARTICLE Open Access
On-treatment biomarkers can improve
prediction of response to neoadjuvant
chemotherapy in breast cancer
Richard J. Bownes1, Arran K. Turnbull1, Carlos Martinez-Perez1, David A. Cameron1,2, Andrew H. Sims1* and
Olga Oikonomidou1,2
Abstract
Background: Neoadjuvant chemotherapy is increasingly given preoperatively to shrink breast tumours prior to
surgery. This approach also provides the opportunity to study the molecular changes associated with treatment
and evaluate whether on-treatment sequential samples can improve response and outcome predictions over
diagnostic or excision samples alone.
Methods: This study included a total of 97 samples from a cohort of 50 women (aged 29–76, with 46% ER+ and
20% HER2+ tumours) with primary operable breast cancer who had been treated with neoadjuvant chemotherapy.
Biopsies were taken at diagnosis, at 2 weeks on-treatment, mid-chemotherapy, and at resection. Fresh frozen
samples were sequenced with Ion AmpliSeq Transcriptome yielding expression values for 12,635 genes. Differential
expression analysis was performed across 16 patients with a complete pathological response (pCR) and 34 non-pCR
patients, and over treatment time to identify significantly differentially expressed genes, pathways, and markers
indicative of response status. Prediction accuracy was compared with estimations of established gene signatures,
for this dataset and validated using data from the I-SPY 1 Trial.
Results: Although changes upon treatment are largely similar between the two cohorts, very few genes were
found to be consistently different between responders and non-responders, making the prediction of response
difficult. AAGAB was identified as a novel potential on-treatment biomarker for pathological complete response,
with an accuracy of 100% in the NEO training dataset and 78% accuracy in the I-SPY 1 testing dataset. AAGAB
levels on-treatment were also significantly predictive of outcome (p = 0.048, p = 0.0036) in both cohorts. This single
gene on-treatment biomarker had greater predictive accuracy than established prognostic tests, Mammaprint and
PAM50 risk of recurrence score, although interestingly, both of these latter tests performed better in the on-
treatment rather than the accepted pre-treatment setting.
Conclusion: Changes in gene expression measured in sequential samples from breast cancer patients receiving
neoadjuvant chemotherapy resulted in the identification of a potentially novel on-treatment biomarker and suggest
that established prognostic tests may have greater prediction accuracy on than before treatment. These results support
the potential use and further evaluation of on-treatment testing in breast cancer to improve the accuracy of tumour
response prediction.
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Introduction
Chemotherapy is among the most common effective treat-
ments for breast cancer, alongside radiotherapy, hormone
therapy, and targeted treatments. Neoadjuvant chemo-
therapy is given prior to surgery with the aim to reduce
the tumour burden and to provide early information on
the response to treatment [1]. Studies have shown patients
with tumours that have a pathological complete response
(pCR) following neoadjuvant chemotherapy are much less
likely to recur than those in women with residual disease
[2]. Neoadjuvant chemotherapy is now considered as the
standard of care in breast cancer and has seen a rise in re-
cent years with data from powered studies suggesting that
the pathological complete response achieved following
neoadjuvant chemotherapy might be a surrogate of good
prognosis [3]. A recent meta-analysis also showed signifi-
cant tumour response and an increase in the rate of
breast-conserving surgery following NACT with good
rates of long-term local recurrence (5.5% vs. 15.9% adju-
vant chemotherapy), however with an increase in the rate
of short-term local relapses (1.35 RR 0–4 years, 1.53 RR
5–9 years) [4].
Neoadjuvant treatment provides a “window of oppor-
tunity” (Fig. 1a), where sequential sampling of a tumour
enables observation of the changes that occur in re-
sponse to treatment to be measured and considered in
the context of response and outcome [5]. Neoadjuvant
therapy studies and pre-surgical treatments allow for a
unique in vivo analysis of tumour treatment response
[6], as well as the possibility of predicting the response
to treatment earlier in the treatment [5]. It has been sug-
gested that on-treatment biomarkers may be superior to
those measured before exposure to treatment [3, 7]. On-
treatment information has already been shown to be in-
formative for the accurate prediction of response to
endocrine therapy [8]. Here, it was found that patients
with elevated Ki67 levels (higher than 10%) at 2 or
4 weeks exhibited resistance to endocrine therapy and
were triaged to neoadjuvant chemotherapy [8]. We have
also demonstrated the potential of on-treatment bio-
markers by developing a four-gene signature which com-
bined pre-treatment expression levels or two biomarkers
(IL6ST and NGFRAP1) with patient-matched 2-week
on-treatment expression levels of two proliferation
Fig. 1 Unsupervised analysis cannot distinguish pre- and on-chemotherapy samples of breast tumours. a Schematic representation demonstrating
sequential sampling of breast tumours during treatment. b PCA analysis of pre- and on-treatment samples from the Edinburgh NEO and I-SPY studies
revealed no significant clustering of patients by time or response group. Red = non-responder, orange = partial responder, blue = complete responder
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markers (ASPM, MCM4) to accurately predict the re-
sponse to endocrine therapy in a blinded independent
validation set [7].
Gene expression-based studies of neoadjuvant chemo-
therapy treatment to date have largely been limited to
studying the association of pre-treatment samples with
pathological response [9, 10]. Patient-matched sequential
sampling gene expression studies have been previously
attempted; however, they have not evaluated the predict-
ive capacity or proposed new on-treatment predictive
biomarkers [11–13].
In this study, we present the largest sequentially sampled
patient-matched analysis of neoadjuvant chemotherapy-
treated breast cancer tumours to evaluate whether on-
treatment biomarkers can improve the accuracy of
predicting response before resection. Numbers of patients
with sequential breast tumour samples are limited, but we
compare and validate our results with the data from the I-
SPY 1 Trial.
Materials and methods
Patients, response criteria, and samples
The NEO study consists of 50 breast cancer patients
with sequentially sampled biopsies at four time points,
pre-treatment (PT, 34 samples), 2 weeks on treatment
(T2, 12 samples), mid-chemo (TM, 23 samples), and at
surgical resection (TS, 24 samples) with three clinically
defined response statuses: complete responders (pCR by
resection), good responders (tumour volume reduction,
but lack of pCR), and non-responders (progressive dis-
ease or small tumour volume changes on treatment). Pa-
tients were of mixed histological grade and HER2 status;
ages ranged from 29 to 76. Patients were primarily
treated with 3 cycles of FEC and docetaxel with Hercep-
tin where appropriate. Three patients received paclitaxel,
one patient received additional carboplatin, one patient
received Epi-cyclophosphamide and paclitaxel, and one
patient received docetaxel and cyclophosphamide. Eli-
gible patients were women with histologically confirmed
invasive breast tumours and with no evidence of distant
metastatic disease, no prior history of malignancy,
and fit enough to receive chemotherapy in the opin-
ion of the responsible clinician irrespective of age. All
cases were discussed at the breast MDM in Edin-
burgh Breast Unit at the Western General Hospital,
and consensus from this meeting was to be treated
with neoadjuvant chemotherapy.
Core needle (16-gauge) biopsies were taken from the
primary breast tumours before treatment (PT) and
between 10 and 14 days after the first dose (T2) of chemo-
therapy. A third sample was taken at the mid-
chemotherapy point day 20–21 (TM), and finally, a core
biopsy was taken from the excision specimen (TS) after it
has been removed prior to submission to pathology. Fixed
and frozen samples of normal and tumour tissue were col-
lected from all specimens.
Gene expression profiling
RNA extraction was performed via Ribo0-RNAseq, and
whole transcriptome sequencing was performed with
Life Sciences Ion AmpliSeq™ Transcriptome Human
Gene Expression Kit. This generated greater than 8M
reads per sample with an average of more than 90% valid
reads for 12,365 targeted genes. Most analyses were per-
formed in R (http://www.r-project.org) using packages
available through CRAN (http://cran.r-project.org/) and
Bioconductor (http://www.bioconductor.org/). Outside
of the R environment, the stand-alone application Mul-
tiple Experiment Viewer (http://mev.tm4.org/) was uti-
lised for pairwise ranked product feature selection, and
DAVID (https://david.ncifcrf.gov/) was used for pathway
identification. Additionally, the python package scikit-
learn [14] was used for unsupervised clustering analysis.
Ninety-seven samples were analysed over 13 AmpliSeq
chips, but no systematic batch effects were evident and
no batch correction was performed within the training
data. Gene expression data for the NEO study has been
made publicly available at the NCBI GEO data reposi-
tory under accession GSE122630.
The I-SPY 1 Trial is composed of patients with inva-
sive breast cancer > 3 cm, or at least one tumour-
positive axillary lymph node [11]. Patients were treated
with an anthracycline-based chemotherapy followed by
taxanes [11]. Samples were normalised and corrected for
background red/green signal; Bioconductor R packages
marray and limma [15] were used to this end. From the
original 221 patients, only 36 had matching pre- and on-
treatment samples, and 39 had matching biopsy and ex-
cision samples; pathological complete response was used
for response criteria. Pairwise gene expression was han-
dled with SAM and follow-up analysis with Ingenuity
Pathway Analysis from QIAGEN Bioinformatics. I-SPY 1
Trial data is hosted at NCBI GEO under accession
GSE32603 [11].
Statistical analysis methods
Principal component analysis (PCA) was performed on
unsupervised gene lists to reduce dimensionality and visu-
alise differences in response at all times and to identify
present differences between patient treatment statuses.
Local Fisher discriminant analysis (LFDA) [16] was used
at each time point to determine if the response groups
could be distinguished with treatment time with a semi-
supervised clustering approach, concurrently with class
advised K-means clustering. LFDA is a form of supervised
dimensionality reduction that maximises between-class
scattering and minimises within class scatter, and is a re-
fined version of normal Fisher discriminant analysis [16];
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this exploratory analysis was used in order to visualise
comparative differences in treatment time, not as a means
of feature selection. Pair-wise significance analysis of mi-
croarrays [17] using the siggenes package in R was used to
consider the consistency of differentially expressed genes
due to treatment in the sequential patient-matched
samples. Rank Product analysis was used to identify
differentially expressed genes between response clas-
ses at each time point. Successive levels of standard p
value (0.05, 0.01, 0.001), without correction for mul-
tiple testing, were used in order to determine the
number of differentially expressed genes, and at lower
p values which the time points had the most strongly
differentiating genes. Significance analysis of microar-
rays was also performed using varying false discovery
rates (1%, 5%, 10%) to try to identify common differ-
entially expressed genes between responders and non-
responders across both datasets at each time point.
Gene score enrichment analysis was used to validate
the time point selection by looking for the highest
number of enriched pathways. The gene list from the
most differential time point (TM) using the NEO
dataset was extracted and used in a random forest
model (10,000 trees, m-try as the square root of the
feature number) using pCR status as the class label
(clinician-identified pCR and non-pCR). The most de-
terministic genes for class prediction were fed into a
classification and regression tree in order to produce
a maximally reduced and repeatable model; this meth-
odology is further described by Turnbull et al. [7].
The CART decision tree was applied to the NEO
dataset for training and tested in the independent I-
SPY 1 dataset using the same cut-points determined
by mean-centring the datasets. This protocol was re-
peated using the gene list from the pre-treatment
only samples, using the same p values and tree con-
figurations for selection. Survival analysis was per-
formed at different time points using the log-rank test.
Intrinsic subtypes, Mammaprint, and risk or relapse
scores were estimated from the gene expression data using
the GeneFu R package [18].
Results
Gene expression differences between responding and
non-responding breast cancer tumours treated with
chemotherapy are subtle and time dependent
Unsupervised principal component analysis was first
used to assess whether sequential patient-matched sam-
ples from patients receiving chemotherapy (Fig. 1b)
would cluster by time point or response status. There
was no significant grouping of patients according to
sampling time: pre, early, or later after chemotherapy in
either the NEO or I-SPY 1 studies (Fig. 1b). There were
no significant differences between the two cohorts in
terms of age, grade hormone receptor, and HER2 status,
and the subset of patients with mid-chemo samples was
not significantly different from the whole NEO cohort
(Table 1). Patient-matched samples enable the pairwise
analysis to look for consistent changes in the gene ex-
pression during treatment. Pairwise significance analysis
of microarray analysis using a 10% false discovery rate
(FDR) identified a relatively small proportion of overlap-
ping upregulated (5%) and downregulated (4%) genes be-
tween the two studies. However, genes that were
increased or decreased in response to treatment in one
study were also clearly and consistently increased or de-
creased in the other study (Additional file 1: Figure
S1A), further suggesting it would be difficult to discrim-
inate responders from non-responders. Indeed, there
was no clustering by response status before or during
treatment (Additional file 1: Figure S1B). These results
likely reflect the considerable inter-patient differences
being substantially larger and more significant than the
subtler commonalities in gene expression of a particular
time point or response class of each tumour. More en-
couragingly, semi-supervised LFDA of each time point
Table 1 Summary of patient characteristics for the NEO study and I-SPY validation set
Characteristics NEO cohort (50) NEO cohort PT-TM pairs (23) p value I-SPY 1 PT-T2 pairs (36) p value
Median age at diagnosis 50.8 50.1 0.8 47
Tumour grade 0.52 0.58
1 0 (0%) 0 (0%) 1 (3%)
2 22 (44%) 12 (52%) 20 (55%)
3 28 (56%) 11 (48%) 15 (42%)
Hormone receptor status 0.24 0.66
Positive 23 (46%) 14 (61%) 24 (67%)
Negative 27 (54%) 9 (39%) 12 (33%)
HER2 status 0.87 0.64
Positive 10 (20%) 5 (22%) 6 (17%)
Negative 40 (80%) 18 (78%) 30 (83%)
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revealed significant separation on-treatment that was
not apparent in pre-treatment samples; this indicated
that there are meaningful differences between the clas-
ses, as early as 2 weeks on-treatment (Fig. 2a). Complete
responders and non-responsive patients were more
clearly separated than partially responding patients.
These results suggest that there is a potentially greater
predictive value looking at on-treatment than pre-
treatment biomarkers.
Responding and non-responding tumours are more
different upon exposure to chemotherapy
In an attempt to quantify the molecular differences be-
tween the response groups at each time point, rank prod-
uct analysis was performed at different standard p values
(0.05, 0.01, and 0.001). This approach was hampered by
different numbers of samples at each time point (with T2
having very few samples); however, the number of genes
differentially expressed at all p values tended to be greater
during rather than before treatment (Fig. 2b). Similar re-
sults were also seen using 1%, 5%, and 10% FDR (Fig. 2b).
The biggest differences between the response classes were
at TM (mid-chemo), which agrees with the LDFA results,
which showed the least amount of overlap of the response
classes at TM. Gene set enrichment analysis across the re-
sponse classes at each time point also demonstrated more
enriched pathways after 2 weeks of treatment (29), mid-
chemo (30), and resection (29), compared to pre-
treatment (18) (Additional file 2: Figure S2A). Next, we
sought to examine common differentially expressed genes
between responders and non-responders across the two
datasets. Far more genes were commonly significantly dif-
ferentially expressed (FDR = 10% between responders and
non-responders on-treatment in the NEO and I-SPY 1
datasets compared with pre-treatment. In accordance with
the LFDA results, more significantly differentially
expressed genes (1814) were observed between on-
treatment samples, with 6% (197), but only one was
common between NEO and I-SPY pre-treatment
(Additional file 2: Figure S2B and Additional file 4). Exam-
ination of the 468 most significantly differentially
expressed genes (p < 0.001) between responders and non-
responders in the NEO dataset at mid-chemo did not
clearly distinguish between response groups or time points
illustrated by the heatmap in Additional file 3: Figure S3,
further demonstrating that identifying biomarkers of re-
sponse to chemotherapy is very difficult.
We were also keen to evaluate whether the intrinsic
subtype assigned to tumours would alter upon treat-
ment. Looking at the NEO and I-SPY datasets, to-
gether we found that basal tumours were relatively
stable with only 2/19 (11%) tumours changing. More
tumours were classified as Luminal A or normal-like
on-treatment, which likely reflects a reduction in the
expression of proliferation genes during chemotherapy
(Fig. 2c).
AAGAB is a promising potential novel on-treatment
biomarker of response to chemotherapy
The mid-chemo gene list from the NEO dataset (1102
genes, unadjusted p value = 0.01) was fed to a random
forest model for further feature selection and classifica-
tion and regression tree (CART) model, which reported
AAGAB as the most predictive gene for response predic-
tion in the NEO training dataset with 100% accuracy for
pCR prediction on the mid-chemo samples (Fig. 3a).
Validation was conducted completely independently on
publicly available sequentially sampled chemotherapy
data from the I-SPY 1 Trial [10] and reported 76% ac-
curacy using AAGAB at the same expression level on
the scaled and centred expression data at the on-
treatment time point prior to resection (T2). For com-
parison, the pre-treatment only sample gene lists were
put through the same protocol in order to consider
whether highly predictive models could be generated be-
fore chemotherapy. IGF1R was the most predictive pre-
treatment marker with an accuracy of 74% and 63% in
the NEO and I-SPY datasets, respectively (Table 2).
AAGAB was the sixth most accurate predictor (65%,
57%); receiver operator curves show the relative specifi-
city and sensitivity of this marker pre- and on-treatment
(Fig. 3b). Gene expression levels of AAGAB were lower
in responders across all time points in the NEO cohort
but were most significantly different at mid-chemo. In
the I-SPY dataset, AAGAB was significantly lower before
treatment and at excision (Fig. 3c). We wondered
whether AAGAB was lower in responders due to a re-
duction in proliferation, but Pearson correlation analysis
(See figure on previous page.)
Fig. 2 Responders and non-responders are more distinct on than before treatment. a Supervised clustering using local Fisher discriminant
analysis (LFDA) indicates that as early as 2 weeks on treatment, there is a visible separation of the response classes that were unseen in the pre-
treatment samples in the NEO dataset. Red = non-responder, orange = partial responder, blue = complete responder. b Greater numbers of
genes are under and overexpressed between responders and non-responders on treatment. The three lines represent different statistical thresholds
(*p < 0.05, **p < 0.01, and ***p < 0.001 or FDR = 10%, FDR = 5%, and FDR = 1%, gene lists are in Additional file 4: Tables S2 and S3) in the NEO dataset. c
Sankey diagram illustrating the proportions of tumours that change or maintain PAM50 intrinsic subtype during chemotherapy treatment. Whilst basal
subtypes remain mostly stable, the composition of the cohort changes with treatment time, which may help to identify responsive or non-responsive
patients. PT = pre-treatment, T-ON = on-treatment
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with common proliferation-associated genes (TOP2A,
BUB1, MKI67, MCM2, FOXM1, and PCNA) demon-
strated no significant correlation to any of these genes
(Fig. 3d), suggesting that AAGAB is independent of pro-
liferation. Survival analysis demonstrated that response
status predicted by AAGAB level, at mid chemo in the
NEO study and at 2 weeks in the I-SPY 1, was signifi-
cantly associated with the outcome (NEO p = 0.048, I-
SPY 1 p = 0.0036) (Fig. 3e). Interestingly, the level of
AAGAB before treatment was not associated with the
outcome in either cohort (p = 0.71 and p = 0.2, Fig. 3e).
None of the other top 10 pre- or on-treatment markers
was significantly associated with the outcome in both
datasets (Table 2); only one gene (ARF5) was associated
with the outcome in the NEO dataset (p = 0.004). Taken
together, the single gene on-treatment biomarker
AAGAB appears to outperform novel pre-treatment
markers and established prognostic tests in predicting
pCR and long-term outcome to chemotherapy.
Comparison of pre- and on-treatment predictions of
response and outcome
We were also keen to assess whether estimations of estab-
lished prognostic signatures might be different upon treat-
ment and if on-treatment might be more accurate. All and
almost all responding patients were predicted to have poor
(See figure on previous page.)
Fig. 3 AAGAB is a promising on-treatment biomarker of chemotherapy response and outcome. a CART analysis identified AAGAB as a possible
biomarker from the Edinburgh NEO dataset and was 100% accurate at predicting pCR in the training data and 76% accurate in the I-SPY 1
validation set. b The ROC curves highlight the difference in on-treatment and pre-treatment accuracy and selectivity. c Strip charts showing the
level of AAGAB in responding and non-responding patients across time points. d AAGAB showed no significant (Pearson) correlation with
established markers of proliferation in the NEO dataset, indicating it does not seem to be a downstream proxy of their regulation. e Kaplan-Meier
plots demonstrate that on-treatment, but not pre-treatment, levels of AAGAB were significantly associated with the outcome in both
cohorts. p values are log-rank test
Table 2 Comparison of pre- and on-treatment biomarkers for predicting response and outcome. Evaluation of the performance of
the top 10 pre- and on-treatment genes identified for predicting pathological response in the NEO dataset
Response accuracy Response AUC Outcome (log-rank)
NEO I-SPY NEO I-SPY NEO I-SPY
On-treatment
AAGAB 100% 78% 1.00 0.63 0.048 0.0036
ZNF165 88% 54% 0.91 0.57 0.26 0.70
KRTCAP3 79% 52% 0.85 0.56 0.81 0.49
RFC2 79% 40% 0.85 0.35 0.51 0.44
C20orf151 70% NA 0.75 NA 0.36 NA
ARF5 70% 43% 0.75 0.36 0.0038 0.20
BSPRY 70% 48% 0.75 0.49 0.47 0.19
NGRN 58% NA 0.66 Na 0.53 Na
CHST7 29% 46% 0.21 0.52 0.65 0.40
SLC18B1 25% Na 0.18 NA 0.55 NA
Pre-treatment
IGF1R 74% 63% 0.76 0.69 0.36 0.11
CTNNB1 71% 49% 0.73 0.46 0.60 0.40
SLC20A2 71% 56% 0.72 0.57 0.063 0.56
HMGCL 68% 47% 0.67 0.45 0.10 0.97
ST6GALNAC5 68% 52% 0.69 0.53 0.6 0.28
AAGAB 65% 57% 0.65 0.58 0.71 0.20
C1orf51 62% NA 0.61 NA 0.12 NA
KRTCAP3 62% 54% 0.63 0.57 0.78 0.78
SETDB2 50% 49% 0.48 0.51 0.29 0.15
FADS2 29% 48% 0.27 0.5 0.14 0.73
NA not available, gene not represented in I-SPY dataset; AUC area under curve. Bold indicates significant p-values. Italics indicate training prediction percentages
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outcomes with the estimated Mammaprint [19], PAM50
[20], or rorS [21] signatures in pre-treatment samples of
the NEO cohort, whereas around half of the responding
patients were predicted as good outcome using on-
treatment data (Fig. 4a). Overall accuracy improved by 2–
8% using on- rather than pre-treatment data; however,
improvement in the predictive power of these tests was
not uniform between response classes. Good outcome
Fig. 4 On-treatment signatures more accurately predict pathological response and outcome than pre-treatment. a A greater proportion of
patients with pathological response are predicted as responders with estimations of molecular signatures on-treatment than pre-treatment.
Concordance between patients predicted as high and low risk across time is poor, but the positive predictive value of these tests increase with
treatment. For PAM50 subtypes, normal-like and Luminal A are considered good prognosis and basal/Luminal B/HER2-enriched are considered
poor outcome. Red = predicted poor outcome, blue = predicted good outcome. b Forrest plots to compare molecular signatures and AAGAB
before and on-treatment combining both datasets, except where indicated* due to individual sample data unavailable for I-SPY 1 patients
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predictions for responders to neoadjuvant chemotherapy
saw an aggregate increase in predictive power from 11 to
44.4%, whilst poor outcome predictions for non-
responders saw a moderate decrease in accuracy, 75 to
63%. None of the gene expression signatures either pre-
or on-treatment or established prognostic markers (NPI,
Grade, Her2 status) was significantly associated with the
outcome in contrast to the remarkable performance of
on-treatment measurement of AAGAB (Fig. 4b).
Discussion
Determining molecular differences between tumours to
select the most effective treatment is the defining feature
of precision oncology. Accurately predicting which pa-
tients will respond to treatment before exposure relies
on a highly specific target. In breast cancer, ER status is
a good indicator of response to endocrine treatment, but
resistance, both primary and acquired, is common.
Chemotherapy is an unselective treatment, relying on
cancer cells growing faster than normal cells. The results
presented here, along with others [7, 8], suggest on-
treatment biomarkers have improved value in predicting
whether tumours respond to treatment and are associ-
ated with the outcome. Changes in gene expression in
sequential patient-matched were fairly consistent in re-
sponse to chemotherapy across two independent data-
sets, regardless of the response status. Identifying
molecular markers between responding and non-
responding tumours was much more challenging. We
previously demonstrated that lobular and ductal breast
cancers respond to endocrine treatment in the same
way, despite clear histological and molecular distinctions
that are apparent and maintained on-treatment [22],
demonstrating that pre-treatment variations do not ne-
cessarily lead to differences in response. The results of
this study are somewhat exploratory, rather than defini-
tive, but further illustrate the considerable potential
value of on-treatment sampling.
There are no universally agreed-upon markers predict-
ive of response to chemotherapy, and the few that have
been investigated in the neoadjuvant setting typically
centre around established markers including ER, P53
HER2, and Ki-67 [23]; thus, the introduction of new
novel biomarkers can expand the currently available
clinical options for physicians. A study published over a
decade ago stated that the differences in gene expression
between responders and non-responders to neoadjuvant
chemotherapy must be rather subtle [12]. The results
presented here confirm this statement; however, our re-
sults suggest that on-treatment biomarkers may provide
important information for predicting response.
As cancer is inherently a proliferative disease, measur-
ing the change in markers of proliferation on-treatment
is logical and genes like ki-67 have been demonstrated
previously to be potentially a new clinical tool for dis-
ease prognosis and prediction [24, 25]. It is therefore all
the more interesting that the potentially novel biomarker
identified in this study, AAGAB is not tightly correlated
with known markers of proliferation. AAGAB has pri-
marily been studied for its role in punctate palmoplantar
keratoderma [26] and the role of adaptin in the clathrin-
independent endocytosis of epidermal growth factors.
The level of AAGAB was found to be prognostic of re-
sponse (p < 0.001) in renal cancers (favourably) and in
thyroid cancers (unfavourably) from the TCGA study,
and expression is elevated in breast cancer, relative to
the normal breast (p < 0.001). However, the exact role of
AAGAB in breast cancer is currently unclear and poten-
tially warrants further investigation. Clearly, further val-
idation of the role of AAGAB in breast cancer is
warranted and will be performed as new neoadjuvant
chemotherapy datasets become available. This study
supports the use and identification of genes or markers
from on-treatment biopsies as a tool for improving pa-
tient response classification. We propose that the use of
on-treatment samples offers valuable insight into the dy-
namic changes correlated with response, and submit our
findings as support for continued neoadjuvant sampling,
and novel biomarker generation.
Conclusion
We have identified AAGAB as a novel on-treatment bio-
marker for accurate prediction of pCR and outcome in
patients treated with neoadjuvant chemotherapy. A
semi-supervised analysis and evaluation of estimations
of established molecular signatures also highlight the po-
tential value of on-treatment biomarkers. Combining
on-treatment biomarkers with known clinical prognostic
factors could further improve the accuracy of response
predictions and deserve further study. On-treatment ex-
pression changes in the neoadjuvant setting may offer
greater possibilities for the identification and creation of
more future novel biomarkers.
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Additional file 1: Figure S1. A, Pairwise significant analysis of
microarrays (FDR = 10%) demonstrating that whilst only a relatively small
proportion of genes are significantly up- or downregulated in response
to chemotherapy in both datasets, overall changes in patient-matched
sequential samples response to treatment are highly consistent. Red =
upregulated, blue = downregulated on- relative to pre-treatment. Gene
lists are in Additional file 4: Table S1. B, Unsupervised principal compo-
nent analysis cannot distinguish responding from non-responding breast
tumours receiving chemotherapy, before or on-treatment. (JPG 126 kb)
Additional file 2: Figure S2. A, Gene set enrichment analysis (GSEA)
results showing greater numbers of enriched pathways between
responders and non-responders on-treatment compared to pre-
treatment in the NEO dataset. B, Venn diagrams indicating that there
were many more overlapping significantly differentially expressed genes
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between responders and non-responders across the two studies on-
treatment compared to pre-treatment. Gene lists are for FDR = 10% (see
Additional file 4: Table S3). (JPG 72 kb)
Additional file 3: Figure S3. Heatmap of the 468 most significantly
differentially expressed genes (p < 0.001) between responders and non-
responders in the NEO dataset at mid-chemo, demonstrating rather poor
separation between the response groups and time points. Gene list is in
Additional file 4: Table S2. (JPG 91 kb)
Additional file 4: Table S1. Gene lists of pairwise analysis of pre- and
on-treatment sequential patient-matched samples from NEO and I-SPY
datasets using Significance analysis of microarrays with FDR = 10%.
Table S2. Gene lists distinguishing between responders and non-
responders at different time points across the NEO and ISPY datasets
using rank product analysis with p < 0.05, p < 0.01, and p < 0.001. Pre-
treatment (TP), 2 weeks (T2), mid-chemo (TM), and surgery (TS). Table S3.
Gene lists distinguishing between responders and non-responders at
different time points across the NEO and I-SPY datasets using significance
analysis of microarrays with FDR = 10%, FDR = 5%, and FDR = 1%.
Pre-treatment (TP), 2 weeks (T2), mid-chemo (TM), and surgery (TS).
(XLSX 1184 kb)
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